ReviewSeminars in thrombosis and hemostasis2020
Vascular Nanomedicine: Current Status, Opportunities, and Challenges.
Review in Seminars in thrombosis and hemostasis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Organelle-Targeted Nanotherapeutics for Parkinson's Disease: From Pathogenesis to Preclinical Strategies and Translational Challenges.International journal of nanomedicine · 2026Review
- Thrombolytic therapy of human black hair and Au drug-loaded nanocapsules in vivo and in vitro based on near infrared II laser response.Journal of materials science. Materials in medicine · 2025Article
- Harnessing nanoparticles for reshaping tumor immune microenvironment of hepatocellular carcinoma.Discover oncology · 2025Review
- Innovative Approaches and Future Directions in the Management and Understanding of Varicose Veins: A Systematic Review.ACS pharmacology & translational science · 2024Review
- Exploring synthesis and applications of green nanoparticles and the role of nanotechnology in wastewater treatment.Biotechnology reports (Amsterdam, Netherlands) · 2024Review
- Direct delivery of plasmin using clot-anchoring thrombin-responsive nanoparticles for targeted fibrinolytic therapy.Journal of thrombosis and haemostasis : JTH · 2023Article
- Current trends and future perspectives of stroke management through integrating health care team and nanodrug delivery strategy.Frontiers in cellular neuroscience · 2023Review
- Beyond the thrombus: Platelet-inspired nanomedicine approaches in inflammation, immune response, and cancer.Journal of thrombosis and haemostasis : JTH · 2022Review
- Platelet-inspired nanomedicine in hemostasis thrombosis and thromboinflammation.Journal of thrombosis and haemostasis : JTH · 2022Review
- Nanoparticle personalized biomolecular corona: implications of pre-existing conditions for immunomodulation and cancer.Biomaterials science · 2022Review
- Targeting regulated cell death in tumor nanomedicines.Theranostics · 2022Review
- Combination targeting of 'platelets + fibrin' enhances clot anchorage efficiency of nanoparticles for vascular drug delivery.Nanoscale · 2020Article
- Nanomedicine: Insights from a Bibliometrics-Based Analysis of Emerging Publishing and Research Trends.Medicina (Kaunas, Lithuania) · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The term "nanotechnology" was coined by Norio Taniguchi in the 1970s to describe the manipulation of materials at the nano (10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.